These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17397243)

  • 1. Impact of pharmacogenomics on clinical practice in oncology.
    Marsh S
    Mol Diagn Ther; 2007; 11(2):79-82. PubMed ID: 17397243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
    Quaranta S; Thomas F
    Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer pharmacogenomics: current and future applications.
    Watters JW; McLeod HL
    Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics and individualized drug therapy.
    Eichelbaum M; Ingelman-Sundberg M; Evans WE
    Annu Rev Med; 2006; 57():119-37. PubMed ID: 16409140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
    Bosch TM; Meijerman I; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
    van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
    Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
    Maitland ML; Vasisht K; Ratain MJ
    Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer pharmacogenomics: SNPs, chips, and the individual patient.
    McLeod HL; Yu J
    Cancer Invest; 2003; 21(4):630-40. PubMed ID: 14533451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
    Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
    Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy.
    Fujita K; Sasaki Y
    Curr Drug Metab; 2007 Aug; 8(6):554-62. PubMed ID: 17691917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer pharmacogenetics.
    Marsh S; McLeod HL
    Br J Cancer; 2004 Jan; 90(1):8-11. PubMed ID: 14710198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.
    Quinones LA; Lavanderos MA; Cayun JP; Garcia-Martin E; Agundez JA; Caceres DD; Roco AM; Morales JE; Herrera L; Encina G; Isaza CA; Redal MA; Larovere L; Soria NW; Eslava-Schmalbach J; Castaneda-Hernandez G; Lopez-Cortes A; Magno LA; Lopez M; Chiurillo MA; Rodeiro I; Castro de Guerra D; Teran E; Estevez-Carrizo F; Lares-Assef I
    Curr Drug Metab; 2014 Feb; 15(2):202-8. PubMed ID: 24524664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.
    Weinshilboum RM
    Cell Mol Neurobiol; 2006; 26(4-6):539-61. PubMed ID: 16807786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
    Stocco G; Crews KR; Evans WE
    Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.
    Mlakar V; Huezo-Diaz Curtis P; Satyanarayana Uppugunduri CR; Krajinovic M; Ansari M
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
    Iyer L
    Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
    Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
    Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.